FlyersRights Files Amicus Brief in Landmark 5th Circuit Case

Airline Passenger Group Argues the District Court Ruling Would Create Two Classes of Passengers Under the Montreal Convention: Those Who Are Disabled and Those Who Are Not FlyersRights, the nation's largest airline passenger nonprofit organization, has filed an amicus curiae brief in the case of Arzu v. American Airlines before the United States Court of […]

RPM Welcomes Binu Panicker as Chief Technology Officer

RPM is pleased to announce the appointment of Binu Panicker as the new Chief Technology Officer. Panicker brings over 26 years of technology and executive leadership experienceto RPM, including time at Covisint, Dassault,and a significant tenure as Chief Technology Officer at FreightVerify, where Binu was instrumental in transforming the company into an AI-powered supply chain

Terra Innovatum Advances USNRC Licensing Process for SOLO Micro-Modular Nuclear Reactor, Moving One Step Closer to Commercialization

Terra Innovatum Announces Progress with the U.S. Nuclear Regulatory Commission (USNRC); Comprehensive Design and Safety Submissions Now Under Regulatory Review NEW YORK CITY, NY / ACCESS Newswire / August 22, 2025 / Terra Innovatum Srl ("Terra Innovatum," or the "Company"), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq:GSRT), a publicly traded

Independent Sales Representatives Struggling With 1099 Taxes – Clear Start Tax Explains How Commission-Based Workers Can Avoid IRS Trouble

Rising tax debt among commission-only sales reps highlights the risks of mismanaged 1099 income and overlooked self-employment taxes. IRVINE, CA / ACCESS Newswire / August 22, 2025 / Independent sales representatives across industries are facing mounting IRS challenges tied to 1099 income, according to Clear Start Tax. With commissions often unpredictable and taxes left solely

EQV Ventures Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants

(NYSE:EVACU), PARK CITY, UT, Aug. 22, 2025 (GLOBE NEWSWIRE) — EQV Ventures Acquisition Corp. II (“EQV II” or the “Company”) announced today that, effective immediately, holders of the units sold in the Company's initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units. The Class A

Nuvini Group Elevates Gustavo Usero to COO

(NASDAQ:NVNI), ~ Positioning for Scalable Growth and Expansion Across Latin America ~ NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading technology conglomerate in the Latin American SaaS sector, today announced that Gustavo Usero has been promoted to Chief Operating Officer, effective Monday, September 1st,

SharpLink Authorizes $1.5 Billion Stock Buyback Program

(NASDAQ:SBET), MINNEAPOLIS, MN, Aug. 22, 2025 (GLOBE NEWSWIRE) — SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world's largest corporate holders of Ether (“ETH”) and prominent industry advocate of Ethereum adoption, today announced that its Board of Directors has authorized a stock repurchase program of up to $1.5 billion of the

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:IPSC), PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global

Rocket Doctor AI Inc Announces Closing of C$4.23m Over-Subscribed Non-Brokered Private Placement of Special Warrants and Units

(CNSX:AIDR),(OTC US:TREIF),(OTCQB:TREIF),(Boerse Frankfurt – Freiverkehr:939), Vancouver, British Columbia, Aug. 22, 2025 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc (formerly Treatment.com AI Inc.). (the “Company“) (CSE: AIDR; OTC: TREIF; FFA: 939) is pleased to announce that, further to its news release dated 25th July, 2025, it has closed its non-brokered private placement of 3,677,400 special warrants

BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the first patient dosed in the expansion cohorts of the SOLARA trial (NCT06706076), the first-in-human trial of BH-30643, a first-in-class, macrocyclic,

Scroll to Top